Shares of global pharmaceutical company, Lupin Limited were trading in the green and 0.5% higher on 16 June after the company signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) to commercialize Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule.  

This strategic agreement will address the treatment of chronic obstructive pulmonary disease (COPD) in China, a market with a growing demand for sophisticated respiratory care solutions.

According to the agreement, SUP will be responsible for getting the necessary regulatory permissions to sell Tiotropium DPI in China. Lupin will continue to have marketing permission and be in charge of the product’s manufacturing.

This collaboration is a strategic step for Lupin to enter the booming Chinese pharmaceutical industry, notably in the respiratory section. 

Tiotropium DPI is a well-known medicine for improving lung function and quality of life in individuals with respiratory disorders such as COPD. 

Lupin expects to considerably grow its presence in China as a result of this agreement. Lupin wants to address the region’s increasing prevalence of respiratory illnesses by providing patients with timely access to innovative and high-quality healthcare treatments.  

This transaction is consistent with Lupin’s overall objective of enhancing its worldwide respiratory health portfolio.

The Chinese market represents a significant opportunity for pharmaceutical businesses, owing to its vast population, growing healthcare awareness, and rising prevalence of chronic diseases such as COPD.  

Tiotropium, the active ingredient in the DPI, is a long-acting anticholinergic bronchodilator that helps to open up the airways in the lungs, making breathing easier. Patients benefit from its distribution via a Dry Powder Inhaler, which is both practical and effective.

This partnership demonstrates Lupin’s commitment to developing and providing vital treatments for respiratory disorders. Partnering with a local business, such as SUP, which has a strong distribution network and knowledge of the Chinese pharmaceutical ecosystem, is critical for effective market entry and commercialization. 

SUP, which has over 18 years of experience in pharmaceutical distribution and management services in China, is well-positioned to lead the regulatory approval process and subsequent market launch of Tiotropium DPI.

At 12:02 pm, the shares of Lupin were trading 0.33% higher at Rs 2,006.10 on NSE.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!